ClinicalTrials.gg
CompletedNCT02725762LIGHTSITE1Updated Jul 13, 2026

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration

An interventional study of LT-300 Active (PBM) and LT-300 Inactive (Sham) in Age Related Macular Degeneration, sponsored by LumiThera, Inc.. Completed at 1 site in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by LumiThera, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 94 studies in Macular Degeneration with a site in Canada — 11 open to participants now, 16 under way, 7 of them phase 3. Macular Degeneration · Canada.

Enrollment
67th of 77
30 · median 180
Started
2016
with 1 other
No phase
18 of 94
3 open now
Registered
53rd of 94
by date

Among the 94 studies in Macular Degeneration with a site in Canada, this one is the 67th largest by enrollment of the 77 interventional ones that give a count, is one of 2 that started in 2016, is one of 18 with no phase, and was the 53rd registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

11 of the 94 studies in Macular Degeneration with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Macular Degeneration with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this research study is to determine if photobiomodulation is an effective treatment of Dry Age-Related Macular Degeneration (AMD) and vision loss associated with the disease.

Read the detailed description

The LumiThera LT 300® Light Delivery System is a stationary desktop instrument used to emit energy in the visible and near infrared spectrum. The LT-300® is designed for the ophthalmologist to use in the treatment of the eye with photobiomodulation (PBM), a process by which cellular mechanisms are induced by light. PBM is being utilized in many indications, such as wound healing, soft tissue injuries, joint pain, myofascial pain, nerve injuries, muscle fatigue for temporary improvement in blood flow and reduction in inflammation. The mechanism of PBM at the cellular level has been ascribed to the activation of mitochondrial respiratory chain components resulting in stabilization of metabolic function and initiation of a signaling cascade, which promotes cellular proliferation and cytoprotection. The LT-300® will provide a preset treatment of PBM to the subject's eye and retinal tissue through the open and closed eyelid.

Approximately 30 subjects meeting the eligibility requirements of the study will be randomly assigned in a 1:1 ratio to receive standard of care treatment for Dry AMD plus PBM treatment with the LT-300 system, or standard of care treatment for Dry AMD plus Sham treatment with the LT-300 system. Subjects randomized to each group will receive two 3-week treatment sessions (9 treatments per session) and follow-up visits extending to one year. The primary objective of the study is to evaluate the safety and efficacy of PBM with respect to visual and anatomical outcomes of subjects with Dry AMD.

03

Conditions studied

  • Age Related Macular Degeneration

Keywords

  • Dry AMD
  • Vision Loss
  • AMD
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of both gender
  • Patients must have dry macular degeneration in the study eye
  • Best corrected visual acuity between 20/40 and 20/200
  • Patients must be competent to sign and have signed a consent form before study entry

Exclusion criteria

Exclusion Criteria:

  • Visually significant cataracts.
  • Presence of a visually significant posterior capsule if prior cataract surgery has been performed.
  • Any visually significant disease process in any ocular structure that would affect vision unrelated to macular degeneration.
  • A patient can be enrolled if only one of their eyes meets the criteria. The other eye may be treated but not included in the study; for example advanced geographic atrophy.
  • Patients with severe disease or unstable medical disorders including cardiovascular, hepatic, renal, neurological, endocrine, gastrointestinal, CNS or life threatening disease or current at the discretion of the investigators
  • Patients who are non-ambulatory or bed ridden
  • Female patients who are pregnant or of as effects of PBM on the developing human fetus are unknown.
  • Patients with a history of Epilepsy
  • Patients with a history of alcohol, drug or substance abuse in the past 6 months
  • Patients deemed uncooperative or non compliant with the requirements of the protocol.
  • Patients who have received any drug or treatment within 30 days prior to study entry.
  • Patients who are not competent to understand and sign consent form.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Photobiomodulation Treatment

    Treatment with Photobiomodulation to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.

    Device: LT-300 Active (PBM)

  • Sham comparator
    Sham Treatment

    Sham treatment to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.

    Device: LT-300 Inactive (Sham)

Interventions

  • DeviceLT-300 Active (PBM)
  • DeviceLT-300 Inactive (Sham)
06

What researchers measure

Primary outcomes

  1. Visual Acuity changes from baseline to month 12.

    Visual acuity will be measured using ETDRS VA letter scoring to test the difference between the sham and treatment subjects in mean change from Baseline to Month 12

    Time frame: Through study completion, an average of one year.

Secondary outcomes

  1. Contrast Sensitivity

    Contrast Sensitivity will be measured using the FACT Contrast Sensitivity Chart to test the difference between the sham and treatment subjects in mean change from Baseline to Month 12

    Time frame: Through study completion, an average of one year.

  2. Optical Coherence Tomography (OCT)

    OCT will be measured using the Spectralis SD-OCT to compare changes in dry AMD pathology.

    Time frame: Through study completion, an average of one year.

07

Study locations

1 site
  • 1929 Bayview Avenue, Unit 117
    Toronto, Ontario M4G 3E8, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Jul 2018 and a completion of Jul 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2016
First posted
Apr 1, 2016
Start
Mar 2016
Primary completionActual
Jul 2018
CompletionActual
Jul 2018
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02725762
Lead sponsor
LumiThera, Inc.
Responsible party
Sponsor
First posted
Apr 1, 2016
Start date
Mar 2016
Primary completion
Jul 2018
Completion
Jul 2018
Last update
Jul 13, 2026

Study contacts

Samuel Markowitz, MD
principal investigator · Private Practice
Robert G Devenyi, MD
principal investigator · Ophthalmologist in Chief and Director of Retinal Services, The Donald K. Johnson Eye Center, University Health Network; Professor of Ophthalmology, The University of Toronto; Vitreoretinal Surgery Lead, The Kensington Eye Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion